| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 5,039 | 7,006 | ||
| General and administrative | 3,006 | 3,085 | ||
| Total operating expenses | 8,045 | 10,091 | ||
| Loss from operations | -8,045 | -10,091 | ||
| Change in fair value of warrant liabilities | 1,811 | 859 | ||
| Loss on issuance of pre-funded warrants | 0 | 0 | ||
| Gain on sale of equipment | 0 | 0 | ||
| Foreign exchange transaction (loss) gain | 0 | 0 | ||
| Grant income | 0 | 415 | ||
| Interest income | 199 | 168 | ||
| Interest expense | 426 | 194 | ||
| Total other (expense), net | -2,038 | -470 | ||
| Net loss | -10,083 | -10,561 | ||
| Foreign currency translation adjustment | 39 | 74 | ||
| Comprehensive loss | -10,044 | -10,487 | ||
| Net loss per common share, basic (in dollars per share) | -0.6 | -0.66 | ||
| Net loss per common share, diluted (in dollars per share) | -0.6 | -0.66 | ||
| Weighted average common shares and pre-funded warrants outstanding, basic (in shares) | 16,692,476 | 16,059,423 | ||
| Weighted average common shares and pre-funded warrants outstanding, diluted (in shares) | 16,692,476 | 16,059,423 | ||
Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc. (ELTX)